**Supplementary Figure Legends**

**Supplementary Figure S1:** *In vivo* and *in vitro* effects of ZA on apoptosis. Representative microphotographs of immunohistochemical staining of apoptosis analysis (TUNEL) in OVCAR-5 (A) and HeyA8-MDR (B) *in vivo* models. TUNEL-positive cells were counted in 5 random fields per slide, one slide per mouse, n=10 mice per group. Means ± SD. \*, *P*<.05; \*\*, *P*<.001; \*\*\*, *P*<.0001 versus saline solution. Western blotting results for cleaved PARP-1 (C) and cleaved caspase-3 (D) in HeyA8 MDR cells treated with ZA. Vinculin and β-actin were used as a loading control.

**Supplementary Figure S2:** Nab-paclitaxel inhibits tube formation. EC-RF24 cells were treated with nab-paclitaxel for 72 h and then incubated in Matrigel 6 h. (A) The number of nodes were significantly lower in the cells treated with nab-paclitaxel as compared with the untreated cells. Means ± SD. \*\*, *P*<.001; \*\*\*, *P*<.0001.

**Supplementary Figure S3:** RPPA analysis in HeyA8 MDR treated with ZA. (A) There was a decrease in Paxillin, PI3K and EGF; and increased in cleaved caspase-7 and 9. Red color shows upregulation of proteins in response to ZA and green color downregulation.

**Supplementary Figure S4:** Functional changes induced by ZA in HeyA8 MDR. Significantly changed proteins were analyzed with Ingenuity Pathway Analysis and the top ten scoring hits are shown.

**Supplementary Figure S5:** ZA decreases angiogenic factors (A) in HeyA8 MDR (VEGF-C) and (B) Ovcar-5 (VEGF-C, HGF, IL-8, G-CSF, follistatin and PLGF) cells. Means ± SD. \*, *P*<.05; \*\*, *P*<.001; \*\*\*, *P*<.0001. Immunoblotting of unprenylated Rap1A in HeyA8-MDR and OVCAR-5 cells (C); and SKOV3-TR and A2780-CP20 (D). β-Actin was used as a loading control.

**Supplementary Figure S6:** ZA inhibits cell invasion of (A) SKOV3-TR and (B) A2780-CP20 cells. The number of invading cells was significantly lower in the cells treated with ZA compared with the untreated cells. Means ± SD. \*\*, *P*<.001; \*\*\*, *P*<.0001. (C) Rac1 is required for EC tube formation. (D) Immunoblotting of Rac1 silencing.